Disclaimer: This deck is not to be used for investment purposes. The dates, schedules, and pricing are examples.
The world's first in-vitro diagnostic platform, about the size of a postage stamp, for multi-step enzyme-linked immunoassays

Autonomous, fluid activated valve inside a cellulose paper test strip

Technology under exclusive license agreement from URI
Problem

Large, fully equipped labs are expensive for running tests and can take days to register results

Access to lab testing is not available to patients without an order from their physician
Solution

Lower testing cost vs full lab setup

Rapid diagnostics

Ease of usability for patients

OTC accessible – patients can use before seeing their physician
Team

Constantine Anagnostopoulos, Ph.D.,
President, Co-founder

Mohammed Faghri, Ph.D.,
Co-Founder and Scientific Advisor

To be hired
Operations Manager

To be hired
Sales Consultant
Screening test in the US for infectious diseases (i.e. influenza)

Consumer OTC – will purchase it before seeing their doctor

Lower bar to break into the market with low cost of development

Relatively low regulations for screening test vs. diagnostic test on which a course of treatment will be based
Product Vision/Core Technology
Competition

CHEMBIO DIAGNOSTIC SYSTEMS

ID NOW™

CORIS BIO CONCEPT
Clinical Laboratory Improvement Amendments (CLIA)

Regulates all facilities in the US that perform laboratory testing on human specimens for health assessment or the diagnosis, prevention, or treatment of disease

CLIA waived tests are cleared by the FDA for home use

Waived tests must be simple and have a low risk for erroneous results

This does not mean that waived tests are completely error-proof.
Primary patent filed in 2014

Patent pertains to a simple and inexpensive method of creating a multi-channel ELSA

Patent has over 15 years of protection based on filing date
# Project Timetable

## Tasks

<table>
<thead>
<tr>
<th>Tasks</th>
<th>Year 1</th>
<th>Year 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Packaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pilot</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA Submission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manufacturing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FUNDING</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series B</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Financial Projection

<table>
<thead>
<tr>
<th>Year</th>
<th>COGS</th>
<th>Sales Price</th>
<th>Volume</th>
<th>Top Line</th>
<th>20% EBITDA</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>$4</td>
<td>$8</td>
<td>x 1,000,000</td>
<td>$8M</td>
<td>$2M</td>
<td>$20M</td>
</tr>
</tbody>
</table>

- 2019: COGS $4, Sales Price $8, Volume 1,000,000, Top Line $8M, 20% EBITDA $2M, Value $20M
Exit Plan

Move to rapid diagnostic means there are many potential acquirers such as Tamiflu, Johnson & Johnson, or CVS/Aetna for complimentary testing.